Af­ter 7 years in stealth, UC Berke­ley spin­out Nodexus emerges with an RA Cap­i­tal-backed Se­ries A

A new com­pa­ny emerged from stealth this morn­ing in San Fran­cis­co Bay, and it’s one fo­cused on re­search tech­nol­o­gy.

Nodexus, a bio com­pa­ny that de­vel­ops au­to­mat­ed live cell char­ac­ter­i­za­tion and iso­la­tion tech­nolo­gies, an­nounced its launch this morn­ing with a Se­ries A net­ting it $30 mil­lion.

Even though Nodexus does not de­vel­op its own drugs, the Se­ries A was led by ma­jor biotech in­vestor RA Cap­i­tal Man­age­ment, with par­tic­i­pa­tion from Cal­i­for­nia VC fund Sec­tion 32 and some pre­vi­ous in­vestors. This comes at the same time Nodexus brings on a new board mem­ber: for­mer pres­i­dent at BD Bio­sciences Bill Rhodes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER